CMPX Files 8-K; Furnishes Q2 Results, Earnings Slides and Presentation

Rhea-AI Filing Summary

Compass Therapeutics furnished a Current Report on Form 8-K announcing that it issued a press release with financial results for the quarter and six months ended June 30, 2025. The press release is included as Exhibit 99.1. The company also furnished the slides presented on its second quarter earnings call as Exhibit 99.2 and its August 2025 corporate presentation as Exhibit 99.3. The filing states that the materials in Item 7.01 (including Exhibit 99.2) are being furnished and not filed, and thus are not subject to Section 18 liabilities or automatically incorporated by reference in other filings. The report discloses the company's common stock trades under the symbol CMPX on the NASDAQ Capital Market. No financial figures are included within the 8-K itself; detailed results are provided in the furnished press release.

Positive

• Press release furnished as Exhibit 99.1 announcing quarter and six-month results for the period ended June 30, 2025
• Earnings call slides and corporate presentation furnished as Exhibits 99.2 and 99.3, providing investor presentation materials

Negative

• No financial figures or operational metrics are included in the 8-K text; investors must review Exhibit 99.1 for results
• Item 7.01 materials are furnished, not filed, meaning they are not subject to Section 18 liability and are not automatically incorporated by reference into other filings

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished via Form 8-K; investors must consult the press release for the actual financial metrics.

The filing primarily notifies investors that Compass Therapeutics has released its quarterly and six-month financial results and provided accompanying presentation slides. The 8-K furnishes Exhibits 99.1 through 99.3 and an Inline XBRL cover page, but does not itself present income statement, balance sheet, or cash flow figures. The explicit statement that Item 7.01 materials are furnished, not filed, limits their regulatory incorporation and Section 18 liability. For valuation or performance analysis, the press release and slides must be reviewed directly.

Corporate Governance Expert

TL;DR: Procedural disclosure consistent with Reg FD and standard 8-K practice; material content resides in the exhibits rather than the filing text.

The document follows conventional governance practice by furnishing earnings communications and investor presentation materials as exhibits. Notably, the company marks the Item 7.01 content as furnished rather than filed, which is an explicit legal distinction reducing the risk of retroactive liability under Section 18. The filing confirms exchange listing and emerging growth status checkbox but contains no executive changes, material transactions, or legal disclosures. Materiality for investors depends on the numerical results in Exhibit 99.1, which are not reproduced in this report.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000173802100017380212025-08-112025-08-11iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 11, 2025

_______________________________

Compass Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2025, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

A copy of the slides presented during the second quarter earnings call is furnished as exhibit 99.2 and the Company’s August 2025 corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Exhibit
99.1		Press Release dated August 11, 2025 (furnished pursuant to Item 2.02)
99.2		Corporate presentation - Earnings Call August 11, 2025
99.3		Corporate presentation of Compass Therapeutics, Inc. dated August 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.
Date: August 11, 2025	By:	/s/ Neil Lerner
		Neil Lerner
		Chief Accounting Officer

FAQ

What did Compass Therapeutics (CMPX) disclose in this Form 8-K?

The company furnished a press release announcing financial results for the quarter and six months ended June 30, 2025 and provided earnings call slides and a corporate presentation as exhibits.

Which exhibits were attached to the 8-K for CMPX?

Exhibit 99.1 (press release), Exhibit 99.2 (earnings call slides), Exhibit 99.3 (August 2025 corporate presentation), and Exhibit 104 (Inline XBRL cover page).

Are the Item 7.01 materials in the CMPX 8-K considered filed with the SEC?

No. The filing states that the Item 7.01 materials (including Exhibit 99.2) are being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

Does this 8-K include the company's financial statements?

No. The 8-K does not contain financial statements or numeric results; the press release (Exhibit 99.1) contains the detailed financial information.

What is Compass Therapeutics' ticker and exchange as stated in the filing?

The company's common stock trades under the symbol CMPX on the NASDAQ Capital Market.